Bio-Rad Labs Inc. A diskutieren
Bio-Rad Labs Inc. A
WKN: 865406 / Symbol: BIO / Name: Bio Rad / Aktie / Ausrüstung & Versorgung / Mid Cap /
252,00 €
0,64 %
Bio-Rad Laboratories, Inc. (NYSE: BIO) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $550.00 price target on the stock.
Ratings data for BIO provided by MarketBeat
Bio-Rad Laboratories, Inc. (NYSE: BIO) had its price target raised by analysts at Royal Bank of Canada from $522.00 to $524.00. They now have an "outperform" rating on the stock.
Ratings data for BIO provided by MarketBeat
Bio-Rad Laboratories, Inc. (NYSE: BIO) had its price target lowered by analysts at Wells Fargo & Company from $550.00 to $525.00. They now have an "overweight" rating on the stock.
Ratings data for BIO provided by MarketBeat
Bio-Rad Laboratories, Inc. (NYSE: BIO) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $395.00 price target on the stock.
Ratings data for BIO provided by MarketBeat
Bio-Rad Laboratories, Inc. (NYSE: BIO) had its price target lowered by analysts at Royal Bank of Canada from $484.00 to $480.00. They now have an "outperform" rating on the stock.
Ratings data for BIO provided by MarketBeat
Bio-Rad Laboratories, Inc. (NYSE: BIO) had its price target raised by analysts at UBS Group AG from $395.00 to $420.00. They now have a "buy" rating on the stock.
Ratings data for BIO provided by MarketBeat
Bio-Rad Laboratories, Inc. (NYSE: BIO) had its price target lowered by analysts at UBS Group AG from $420.00 to $385.00. They now have a "buy" rating on the stock.
Ratings data for BIO provided by MarketBeat
Bio-Rad Laboratories, Inc. (NYSE: BIO) had its price target lowered by analysts at Royal Bank of Canada from $402.00 to $401.00. They now have an "outperform" rating on the stock.
Ratings data for BIO provided by MarketBeat
Bio-Rad Laboratories, Inc. (NYSE: BIO) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $401.00 price target on the stock.
Ratings data for BIO provided by MarketBeat
Bio-Rad Laboratories, Inc. (NYSE: BIO) was upgraded by analysts at Citigroup Inc. from a "neutral" rating to a "buy" rating. They now have a $400.00 price target on the stock, up previously from $350.00.
Ratings data for BIO provided by MarketBeat
Bio-Rad Laboratories, Inc. (NYSE: BIO) had its price target raised by analysts at Royal Bank of Canada from $446.00 to $469.00. They now have an "outperform" rating on the stock.
Ratings data for BIO provided by MarketBeat
Bio-Rad Laboratories, Inc. (NYSE: BIO) had its price target raised by analysts at Citigroup Inc. from $400.00 to $450.00. They now have a "buy" rating on the stock.
Ratings data for BIO provided by MarketBeat
Bio-Rad Laboratories, Inc. (NYSE: BIO) had its price target raised by analysts at Royal Bank of Canada from $369.00 to $481.00. They now have an "outperform" rating on the stock.
Ratings data for BIO provided by MarketBeat
Bio-Rad Laboratories, Inc. (NYSE: BIO) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $481.00 price target on the stock.
Ratings data for BIO provided by MarketBeat
Bio-Rad Laboratories, Inc. (NYSE: BIO) had its price target lowered by analysts at Royal Bank of Canada from $409.00 to $392.00. They now have an "outperform" rating on the stock.
Ratings data for BIO provided by MarketBeat
Bio-Rad Laboratories, Inc. (NYSE: BIO) had its price target lowered by analysts at UBS Group AG from $355.00 to $310.00. They now have a "buy" rating on the stock.
Ratings data for BIO provided by MarketBeat
Bio-Rad Laboratories, Inc. (NYSE: BIO) was upgraded by analysts at Wall Street Zen from a "hold" rating to a "buy" rating.
Ratings data for BIO provided by MarketBeat
Bio-Rad Laboratories, Inc. (NYSE: BIO) had its price target raised by analysts at Royal Bank Of Canada from $387.00 to $409.00. They now have an "outperform" rating on the stock.
Ratings data for BIO provided by MarketBeat
Bio-Rad Laboratories (NYSE:BIO) had its price target raised by analysts at Citigroup Inc. from $350.00 to $375.00. They now have a "buy" rating on the stock.
Ratings data for BIO provided by MarketBeat
Neueste Beiträge
Cantor_Fitzgerald in Visa Inc. A diskutieren